EUCTR2015-004816-39-ES进行中（未招募）1 期
A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 245
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients must have at least 1 standard treatment regimen in the advanced, recurrent or metastatic setting
- •ECOG (Eastern Cooperative Oncology Group) 0-1
- •Men and women 18 years old or older
- •At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 145
排除标准
- •Known central nervous system metastases or central nervous system as the only source of disease
- •Concomitant malignancies
- •Active known or suspected autoimmune disease
- •Uncontrolled or significant cardiovascular disease
- •Major surgery less than 4 weeks before the start of the study
研究者
相似试验
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumaband/or Ipilimumab in Subjects With Advanced Solid Tumors.Advanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2015-004816-39-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO166
尚未招募
不适用
A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination with Nivolumab and/or Ipilimumab in Subjects with Advanced Solid TumorsDuring the Dose Escalation phase the following tumor histologies permitted except primary CNS tumorsNL-OMON47099Bristol-Myers Squibb20
进行中（未招募）
1 期
Study of BMS-986178 Monotherapy or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors.EUCTR2015-004816-39-NLBristol-Myers Squibb International Corporation166
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2016-000603-91-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO235
进行中（未招募）
1 期
Study of BMS-986179 Administered alone and in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 20.0 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864EUCTR2016-000603-91-DEBristol-Myers Squibb International Corporation246